Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss

By Reuters News16:19 (UTC), 1 October 2026 Updated

Oct 1 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:

PHASE 2 COURAGE TRIAL CONFIRMS TREVOGRUMAB PREVENTS LEAN MASS AND MUSCLE LOSS DURING GLP-1 RECEPTOR AGONIST-INDUCED WEIGHT LOSS
REGENERON PHARMACEUTICALS, - TREVOGRUMAB PREVENTS 70% OF MUSCLE LOSS ASSOCIATED WITH SEMAGLUTIDE TREATMENT
REGENERON PHARMACEUTICALS, - PLANS PHASE 2 TRIAL OF TREVOGRUMAB WITH GLP-1 THERAPIES IN OLDER ADULTS
REGENERON PHARMACEUTICALS, - LOWER DOSES OF TREVOGRUMAB WELL TOLERATED WITH 77% EXPERIENCING AT LEAST ONE ADVERSE EVENT

Further company coverage: REGN.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.